Navigation Links
TorreyPines Announces the Adjournment of Its Special Meeting of Stockholders
Date:7/9/2009

LA JOLLA, Calif., July 9 /PRNewswire/ -- TorreyPines Therapeutics, Inc. ("TPTX") announced today that its Special Meeting of Stockholders, which was convened on July 9, 2009, was adjourned to July 16, 2009 at 9:00 a.m., local time, at TPTX's offices located at 11085 North Torrey Pines Road, Suite 300, La Jolla, CA 92130. As discussed in the Proxy Statement distributed to stockholders on or about June 19, 2009, the stockholders of TPTX were scheduled to vote upon a proposal to approve the liquidation and dissolution of TPTX pursuant to a Plan of Liquidation and Dissolution. Sixty-two percent (62%) of TPTX's stockholders failed to return their proxy cards or otherwise indicate their votes with respect to this proposal prior to the start of the Special Meeting. In order to pass, this proposal must be approved by holders of at least a majority of TPTX's outstanding voting shares, and as a result, abstentions and non-votes have the same effect as votes against the proposal.

Ninety-seven percent (97%) of the stockholders present at the meeting in person or voting by proxy approved the proposal to adjourn and reconvene the Special Meeting to permit further solicitation of proxies since there were not sufficient votes at the Special Meeting to approve the Plan of Liquidation and Dissolution. Stockholders who have not voted on the proposals described in the Proxy Statement are encouraged to do so promptly. For stockholders that have already voted on the proposals, no additional action is necessary if you do not wish to change your vote. Proxies may be submitted or revoked at any time prior to the reconvening of the adjourned meeting on July 16, 2009. For assistance in voting your shares, please contact TPTX's investor relations department at 858-623-5665 x158.

Stockholders of TPTX are urged to read the Proxy Statement, which contains important information about the Special Meeting and the proposals to be voted upon and it should be re
'/>"/>

SOURCE TorreyPines Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. TorreyPines Therapeutics to Present at the JMP Securities Healthcare Focus Conference
2. TorreyPines Therapeutics to Present at BMO Capital Markets Focus on Healthcare Conference
3. Gamma Secretase Modulators Show Promise in Alzheimers Disease Animal Model Efficacy Studies, According to Research Conducted by TorreyPines Therapeutics
4. TorreyPines Therapeutics Licenses Intellectual Property from Johns Hopkins Related to Novel Uses of Glutamate Receptor Antagonists for Prevention, Treatment of Stroke, Heart Attack
5. TorreyPines Therapeutics Reports First Quarter 2008 Financial Results and Accomplishments
6. TorreyPines Therapeutics Announces Management Change and Second Quarter 2008 Financial Results
7. TorreyPines NGX426, an Oral AMPA/Kainate Receptor Antagonist, Meets Primary Endpoints in Reducing Capsaicin-Induced Pain in Healthy Subjects
8. TorreyPines Therapeutics, Inc. Hires Advisor to Evaluate Strategic Alternatives
9. HHS Announces $75 Million in Supplemental Funding to States for Pandemic Flu Preparedness
10. CRC Health Group Announces Acquisition of Bayside Marin Recovery Center, San Rafael
11. UHW Announces: Antelope Valley Hospital Caregivers and Board Vote to Ratify First Union Contract With SEIU UHW-West
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/3/2015)... SpineFrontier, a Less Exposure Surgery (LES) technology company, ... market their new sacroiliac joint fusion screw, the SIJ ... and is compatible with both lateral and alternate posterior ... researched and refined by SpineFrontier, the first company to ... conjunction with a sacroiliac joint fusion system like this. ...
(Date:5/2/2015)... As one of only 30 Illinois companies to ... Achievement and Recognition Program (SHARP) certification, Essentra Specialty ... Illinois Department of Labor to host this special event. ... by the Occupational Safety and Health Administration’s (“OSHA”) Onsite ... meet or exceed all of the necessary regulations and ...
(Date:5/2/2015)... “ ActOn ” was featured on NewsWatch ... at the latest and coolest applications on the market for ... and technology expert, conducted the app review and shared with ... organizations to make a difference. , In this material world, ... that aren’t about money, which is why those things should ...
(Date:5/2/2015)... We are pleased to announce the Sun ... one of the Top Workplaces of 2015. , The ... field for their ethics and standards of excellence. The ... their educational efforts. The Delray Recovery Center prides itself ... purpose – to help individuals heal from the disease ...
(Date:5/2/2015)... May 02, 2015 Kare Visits LLC. launched ... for busy caregivers. Kare Visits offers relief for caregivers ... living facilities. According to the Caregiver Action Network, ... average of 20 hours a week caring for an elderly ... cost to hire a nurse, a caregiver is now empowered ...
Breaking Medicine News(10 mins):Health News:Essentra Specialty Tapes is Selected to Host Gov. Rauner and the Workers' Memorial Day Celebration 2Health News:Essentra Specialty Tapes is Selected to Host Gov. Rauner and the Workers' Memorial Day Celebration 3Health News:An Application to Help People Make a Difference Was Featured on NewsWatch Television 2Health News:The Delray Recovery Center Named 2015 Top Workplace 2Health News:Chicagoan Seeks to Transform Industry by Launching an Innovative Elderly Care Solution 2
... vice minister of health in China has sought for more ... organs by patients in their country//. According to him there ... and the actual donations. ,Statistics reveal that 1.5 ... are lucky enough to find organs. In China organs are ...
... come out in support of old wisdom, in order ... health challenges// of today. ,Improving pupil-teacher ... very ethos(institutional culture) of a school will do the ... superiority of aged principles to newer ones such ...
... research conducted by Dr Michael Kisley, a psychologist from the ... more positive// outlook towards life than young people. These findings ... than one hundred and fifty participants took part in this ... neutral and negative aspects of life. The viewing was restricted ...
... on antiretroviral therapy (ART) experience liver enzyme elevation ... advised when prescribing ART in this population. Results ... Antiretrovirals) study indicate that coinfection itself may be ... ,The study investigated whether coinfected individuals on ...
... of AZT, lamivudine, and nevirapine (AZT/3TC/NVP) taken from week ... delivery resulted in significantly reduced HIV levels in breast ... the breast milk of women who were not treated ... Enhancement Against AIDS and Malnutrition) in Mozambique conducted this ...
... The use of medicines to fight cardiovascular disease has been ... past several decades,// as combinations of interventions and medicinal therapy ... ,Two studies has looked at the measurable impact of ... demonstrates that lower doses of therapies may prove to be ...
Cached Medicine News:Health News:'School Sermons' Need a Comeback 2Health News:Study Attributes Elevated Liver Enzymes in HIV/hepatitis to Coinfection Rather Than Antiretrovirals 2Health News:Triple ARV Prophylaxis Reduces Viral Load in Breast Milk 2Health News:Triple ARV Prophylaxis Reduces Viral Load in Breast Milk 3Health News:Triple ARV Prophylaxis Reduces Viral Load in Breast Milk 4Health News:Low-dose Aspirin Beats High-dose After Cardiac Surgery 2Health News:Low-dose Aspirin Beats High-dose After Cardiac Surgery 3
(Date:5/1/2015)... -- Shares of Aerie Pharmaceuticals, Inc. (NASDAQ: AERI ) ... results of the Phase 3 Rocket 1 trail of ... to meet its end points, compelling data from the ... studies. An analyst report on AERI that ... analyst summary, valuation, and recommendation can be viewed by ...
(Date:4/30/2015)... Omnicell, Inc. (NASDAQ: OMCL ), a leading provider of ... announced results for its first quarter ended March 31, ... quarter of 2015 was $116.2 million, up $14.5 million ... down $5.3 million or 4.4% from the fourth quarter ... as reported in accordance with U.S. generally accepted accounting ...
(Date:4/30/2015)... 30, 2015  Tandem Diabetes Care ® , Inc. (NASDAQ: ... the t:slim ® and t:flex™ Insulin Pumps, today reported ... In comparing the first quarter of 2015 ... 53 percent to $12.3 million from $8.1 million , ... 1,723 pumps "Our investment in resources to build ...
Breaking Medicine Technology:All is Not Lost for Aerie Pharmaceuticals - VLM Research Issued by BrokerBank Securities, Inc. 2Omnicell Announces First Quarter 2015 Results 2Omnicell Announces First Quarter 2015 Results 3Omnicell Announces First Quarter 2015 Results 4Omnicell Announces First Quarter 2015 Results 5Omnicell Announces First Quarter 2015 Results 6Omnicell Announces First Quarter 2015 Results 7Omnicell Announces First Quarter 2015 Results 8Omnicell Announces First Quarter 2015 Results 9Omnicell Announces First Quarter 2015 Results 10Omnicell Announces First Quarter 2015 Results 11Omnicell Announces First Quarter 2015 Results 12Omnicell Announces First Quarter 2015 Results 13Omnicell Announces First Quarter 2015 Results 14Omnicell Announces First Quarter 2015 Results 15Omnicell Announces First Quarter 2015 Results 16Omnicell Announces First Quarter 2015 Results 17Omnicell Announces First Quarter 2015 Results 18Omnicell Announces First Quarter 2015 Results 19Omnicell Announces First Quarter 2015 Results 20Omnicell Announces First Quarter 2015 Results 21Omnicell Announces First Quarter 2015 Results 22Omnicell Announces First Quarter 2015 Results 23Omnicell Announces First Quarter 2015 Results 24Omnicell Announces First Quarter 2015 Results 25Omnicell Announces First Quarter 2015 Results 26Omnicell Announces First Quarter 2015 Results 27Tandem Diabetes Care Reports First Quarter 2015 Financial Results 2Tandem Diabetes Care Reports First Quarter 2015 Financial Results 3Tandem Diabetes Care Reports First Quarter 2015 Financial Results 4Tandem Diabetes Care Reports First Quarter 2015 Financial Results 5Tandem Diabetes Care Reports First Quarter 2015 Financial Results 6
... A new study published online today ... NEJM) shows bevacizumab (Avastin) is as effective as ranibizumab ... treating age-related macular degeneration (AMD). The ... Trials" (CATT) study, a pioneering comparative effectiveness trial made ...
... 2011 PharmaNet Development Group, Inc., a leading provider ... and medical device companies, announced today that Valerie Palumbo ... Quality Assurance. "We are very pleased ... President, PharmaNet Development Group. "Valerie brings deep experience in ...
Cached Medicine Technology:Cleveland Clinic-Led Study Finds Bevacizumab as Effective as FDA-Approved Ranibizumab in Treating Macular Degeneration 2Cleveland Clinic-Led Study Finds Bevacizumab as Effective as FDA-Approved Ranibizumab in Treating Macular Degeneration 3Cleveland Clinic-Led Study Finds Bevacizumab as Effective as FDA-Approved Ranibizumab in Treating Macular Degeneration 4
... Knife with BD Xstar Blade includes a ... the blade in prodedure and handling. ... a grind-less process for manufacturing surgical blades. ... and consistency. The arch style, single-bevel ...
Consists of the print and PDA versions of Harrison's Manual of Medicine 15th Edition. Provides high-end medical content via PDA....
Product includes all 15 Lexi-Comps databases. Includes Lexi-drugs, the official reference of the American Pharmacists Association and the National Professional Society of Pharmacists....
... The SphygmoCor Mx Central Blood ... of the SphygmoCor Px system by ... aortic pressure waveform., ,Key cardiovascular parameters ... trended. These parameters include:, Central ...
Medicine Products: